SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

Mediterranean Deli reopens on Franklin Street two years after fire: 'A gathering place'
Mediterranean Deli, a restaurant on 410 W. Franklin St., officially reopened Tuesday night after it closed following a roof fire in July 2023. Shortly after...
Tue Sep 16, 2025

Tyler Hansbrough, Marvin Williams, Other UNC Alumni Buy Professional Pickleball Franchise
Palm Beach will make history as the Palm Beach Royals become the city's first major pro sports franchise, joining Major League Pickleball as its 23rd...
Thu Sep 11, 2025

Tar Heels Take Part In Annual 9/11 Memorial Stair Climb
Hundreds of Tar Heels participated in the annual 9/11 Memorial Stair Climb, hosted by the UNC AROTC in Kenan Stadium on Thursday morning. Participants climbed...
Thu Sep 11, 2025

UNC welcomes largest first-year class ever
UNC enrolled its largest first-year class in school history, a milestone that reflects record interest in a Carolina education. A total of 6,191 new students,...
Tue Sep 9, 2025